GEN Exclusives

More »

GEN News Highlights

More »
Aug 20, 2010

Celgene’s Revlimid Cleared by Japanese Authorities for Treating Deletion 5q MDS

  • The Japanese regulatory authorities granted full marketing approval for Celgene’s Revlimid® therapy as a treatment for patients with myelodysplastic syndromes (MDS) associated with 5q deletion abnormality. This latest clearance for the thalidomide analogue follows on from its approval in Japan in June as combination therapy with dexamethasone for the treatment relapsed or refractory multiple myeloma in patients who have previously received at least one standard therapy. Revlimid will be available in Japan through Celgene’s RevMate™ distribution program.

    Revlimid was the first of Celgene’s small molecule, orally available immunomodulatory IMiDs® compounds to reach the market. The drug is approved in combination with dexamethasone for the second-line treatment of multiple myeloma in over 50 countries across Europe, the Americas, the Middle East, and Asia. In Australia and New Zealand, Revlimid is sanctioned as combination therapy for the treatment of patients whose disease has progressed after one therapy.

    Approval in North America, along with several Latin American countries, Malaysia, Israel, Australia, and New Zealand has also been granted for Revlimid in the treatment of transfusion-dependent anemia caused by low- or intermediate-1-risk MDS associated with deletion 5q cytogenetic abnormalities. Celgene says similar applications are currently being evaluated in other countries. Clinical trials are also ongoing to evaluate Revlimid in the treatment of a range of hematological malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia.  

    Celgene reported net global Revlimid sales of $1.76 billion in 2009, up 28.8% on sales during 2008.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »